---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-226691"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-05-15T20:08:23+00:00"
generated_at: "2026-05-15T20:14:32.216347+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart

## Summary
- Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
- Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.
- CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.
- Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.
- Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-226691
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-05-15T20:08:23+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/rani-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-226691
- JSON: https://secwatch.observer/filing/0001193125-26-226691.json
- Plain text: https://secwatch.observer/filing/0001193125-26-226691.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.7 million, net income $8.0 million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $1.7 million
  - Net income: $8.0 million
  - Result: reported results
  source text: and license agreement with Chugai, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three months ended March 31, 2026 were $1.7 million, compared to $0.2 million for the same period in 2025. The increase of $1.5 million was primarily attributable to the collaboration and license agreement with Chugai. • Research
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm
- Listing & Compliance Notices
  Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm
- Executive change
  Svai Sanford departed as Chief Financial Officer at Rani Therapeutics Holdings, Inc..
  - Action: resign
  - Role: Chief Financial Officer
  source text: On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526226691/0001193125-26-226691-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.